跳至主要内容
临床试验/ISRCTN14585543
ISRCTN14585543进行中(未招募)未知

Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review

Queen Mary University of London0 个研究点目标入组 5,300 人开始时间: 2022年4月27日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
5,300

研究概览

简要总结

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37208139/ (added 22/05/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. General practice with >4000 registered patients
  • 2. Practice lead, or representative, confirms agreement to participate in the study after reading the practice information sheet
  • 3. Practice lead, or representative, confirms practice support introduction of Fib-4 testing for all patients with type 2 diabetes attending for annual review
  • 4. Track record of >85% of patients with type 2 diabetes attending for diabetes review
  • 5. Practice uses EMIS computer system
  • 6. Referral route for fibroscan based on primary care non-invasive score agreed
  • Patient inclusion criteria:
  • 1. Type 2 diabetes
  • 2. Serum biochemistry sample taken alongside diabetes annual review

排除标准

  • 1. Inclusion criteria not met
  • 2. Practice participating in other screening or case-finding study related to liver fibrosis

研究者

相似试验